Pancreatic Cancer UK and University Hospital Birmingham pick up first prize
NICE has commissioned international experts to advise on whether we should adopt a new way of valuing health-related quality of life in England.
Exhibition programme We take part in a number of health and social care exhibitions and conferences throughout the year. Each event gives us the...
NICE news Our monthly newsletter, keeping you up-to-date with important developments at NICE. Subscribe for information on: our latest published and
A fit and energised workforce is less likely to be off sick and more satisfied in their jobs
NICE has hosted a parliamentary reception and awards ceremony in celebration of its 20th anniversary.
Our monthly newsletter for GPs and others working in primary care.
Children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with nusinersen after NICE today (15 May) recommended it following agreement of a deal between the company, Biogen, and NHS England.
A new, lower price for a drug to treat a rarer form of multiple sclerosis in adults has paved the way for its approval by NICE
Jump to: Our Stance on Frequently Asked Questions Our stance on: Statins Our guidance on the risk assessment and reduction
Shared Learning Award 2019 finalist
Shared Learning Award 2019 finalist
Shared Learning Award 2019 winner
NICE’s new guideline is the first to offer comprehensive information on neurological conditions to help non-specialist healthcare professionals to identify people who should be referred for specialist assessment and care.
HealthTech Connect, a new online resource provided by NICE to help identify and support new health technologies as they move from inception to adoption in the UK health and care system was formally launched today (29 April).
Applications must be received by midday on 7 May 2019
All women should be able to access both medical and surgical procedures to terminate their pregnancy, says NICE in draft guidance.
People with asthma will be helped to choose the inhaler that is best for them, and best for the environment, by a new patient decision aid from NICE
Dr David Halpern, What Works national adviser, discusses how NICE has inspired evidence-based decision making across the public sector
Mike Williams, senior evaluator, NSPCC, describes why assessment of children at risk needs to be more adaptive
A promising new lung cancer treatment will be available on the NHS through the Cancer Drugs Fund, thanks to a new NICE recommendation.
NICE has today (28 March) published a summary for healthcare professionals bringing together all its recommendations and other safety advice on the drug valproate.
NICE is embarking on an ambitious multi-year programme that will review the way we produce and present guidance and advice
Organisation was founded in April 1999 to improve outcome for health service users
NICE has published its draft updated guideline on the diagnosis and treatment of high blood pressure (hypertension) for public consultation.
Multimorbidity needs a new model of treatment, the authors explain why and how
Hundreds more people with severe to profound deafness will be eligible for cochlear implants each year, due to updated NICE guidance
Cathy Rodway, Programme Manager at the National Confidential Inquiry into Suicide and Safety in Mental Health (NCISH), tells us why it is important to support the review of self-harm services in local areas
The updated quality standard highlights that authorities should assess planning applications and consider how the effects of traffic-related air pollution may affect local communities.
NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.
More than 60 entries received from organisations across the country which highlight how they put NICE guidance into practice
Karen O’Brien, CDAO leading on Greater Manchester Strategy Implementation Plan, Greater Manchester Health & Social Care Partnership (HSCP), discusses medicines optimisation and the resources available on the NICE website
NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.
The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study.
These two guidelines set out an antimicrobial prescribing strategy that aims to optimise antibiotic use and reduce antibiotic resistance.
People showing erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed without the need for blood tests, NICE says in new guidance.
Angelica experienced abuse aged 12. She shares her story and talks about her role in developing NICE guidance.
NICE is updating its guideline on Alcohol interventions in secondary and further education.
NICE and the Canadian Agency for Drugs and Technology in Health (CADTH) have launched a new collaboration to offer parallel scientific advice to the life sciences industry.
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the Cancer Drugs Fund.
NICE has announced a collaboration with the body which represents life sciences organisations in the UK.
Children and young people can be offered digital cognitive behavioural therapy (digital CBT, also known as computer CBT) as a first-line treatment for mild depression.
Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia.
Explore data about our technology appraisal guidance. Find out about the decisions we make and our ways of working.
Procedure will extend the life of a donor liver by double the length of time compared to now
NICE has published its guideline on the care and support needs of adults with cerebral palsy.
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in draft guidance published today.
Annabel Dawson, lay reviewer for National Institute for Health Research discussed the importance of end of life planning
Physical inactivity is responsible for one in six deaths and is believed to cost the UK £7.4 billion each year, including £900 million to the NHS
Another potentially life-changing treatment should be available to people with a severe form of asthma, NICE says.